A number of prostate cancer (PCa)-specific genomic aberrations (denominated BRCAness genes) have been discovered implicating sensitivity to PARP inhibition within the concept of synthetic lethality. Recent clinical studies show favorable results for the PARP inhibitor Olaparib used as single agent for treatment of metastatic castration-resistant PCa. Using 2D and 3D cell culture models mimicking the different treatment and progression stages of PCa we evaluated a potential use for Olaparib in combination with first-line endocrine treatments, androgen deprivation and complete androgen blockade and as a maintenance therapy sequenced to endocrine therapy. We demonstrate that the LNCaP cell line possessing multiple aberrations in BRCAness genes is sensitive to Olaparib. Additive effects of Olaparib combined to endocrine treatments in LNCaP are noted. In contrast, we find that the TMPRSS2:ERG-fusion positive cell lines VCaP and DuCaP do not show signs of synthetic lethality, but are sensitive to cytotoxic effects caused by Olaparib. In consequence, additive effects of Olaparib with endocrine therapy were not observable in these cell lines, showing the need for synthetic lethality in combination treatment regimens. Additionally, we show that PCa cells remain sensitive to Olaparib treatment after initial androgen deprivation implicating a possible use of Olaparib as maintenance therapy. In sum, our pre-clinical data recommend Olaparib as a synthetic lethal treatment option in combination or sequenced to first-line endocrine therapy for PCa patients with diagnosed BRCAness.

A number of prostate cancer (PCa)-specific genomic aberrations (denominated BRCAness genes) have been discovered implicating sensitivity to PARP inhibition within the concept of synthetic lethality. Recent clinical studies show favorable results for the PARP inhibitor Olaparib used as single agent for treatment of metastatic castration-resistant PCa. Using 2D and 3D cell culture models mimicking the different treatment and progression stages of PCa we evaluated a potential use for Olaparib in combination with first-line endocrine treatments, androgen deprivation and complete androgen blockade and as a maintenance therapy sequenced to endocrine therapy. We demonstrate that the LNCaP cell line possessing multiple aberrations in BRCAness genes is sensitive to Olaparib. Additive effects of Olaparib combined to endocrine treatments in LNCaP are noted. In contrast, we find that the TMPRSS2:ERG-fusion positive cell lines VCaP and DuCaP do not show signs of synthetic lethality, but are sensitive to cytotoxic effects caused by Olaparib. In consequence, additive effects of Olaparib with endocrine therapy were not observable in these cell lines, showing the need for synthetic lethality in combination treatment regimens. Additionally, we show that PCa cells remain sensitive to Olaparib treatment after initial androgen deprivation implicating a possible use of Olaparib as maintenance therapy. In sum, our pre-clinical data recommend Olaparib as a synthetic lethal treatment option in combination or sequenced to first-line endocrine therapy for PCa patients with diagnosed BRCAness.